Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05431387
Other study ID # ACH-CYT-10
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 13, 2022
Est. completion date February 28, 2023

Study information

Verified date February 2024
Source Achieve Life Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the safety profile of 3 mg cytisinicline administered TID for 12 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date February 28, 2023
Est. primary completion date February 28, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female subjects, age = 18 years. 2. Test positive for cotinine using the Alere iScreen® OFD Cotinine Oral Fluid Screening Device (Positive testing at = 30 ng/mL cotinine level). 3. Current daily nicotine-containing electronic cigarette usage as recorded in a screening diary for at least 7 consecutive days. Willing to bring the e-cigarette or nicotine device used to the clinical site so that the specific product type, flavor, and nicotine level can be documented. 4. Willing to initiate study treatment on the day after randomization and set a quit date within 7-14 days of starting treatment. 5. Willing to actively participate in the study's vaping cessation behavioral support provided throughout the study. 6. Able to fully understand study requirements, willing to participate, and comply with dosing schedule. 7. Sign the Informed Consent Form. Exclusion Criteria: 1. Currently smoking, or having smoked within 4 weeks prior to study randomization, any combustible cigarettes, other combustible tobacco products or non-combustible tobacco products (such as heat not burn products) (i.e., dual users). 2. Expired carbon monoxide (CO) levels = 10 ppm, indicating recent combustible tobacco use. 3. More than 1 study participant in same household during the study treatment period. 4. Known hypersensitivity to cytisinicline or any of the excipients. 5. Positive urinary drugs of abuse screen determined within 28 days before the first dose of cytisinicline (Note: tetrahydrocannabinol (THC) is not part of the abuse screen). 6. Clinically significant abnormal serum chemistry or hematology values within 28 days of randomization (i.e., requiring treatment or monitoring). 7. Clinically significant abnormalities in 12-lead electrocardiogram determined after minimum of 5 minutes in supine position within 28 days of randomization (i.e., requiring treatment or further assessment). 8. Recent history (within 3 months) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure. 9. Current uncontrolled hypertension (blood pressure = 160/100 mmHg). 10. Documented diagnosis of schizophrenia or bipolar psychiatric illness; currently psychotic; having suicidal ideation within the last 3 months (corresponding to question 4 or 5 on the Columbia - Suicide Severity Rating Scale [C-SSRS]); or current symptoms of moderate to severe depression (depression score = 11 on the HADS) within the last 3 months. 11. Renal impairment defined as a creatinine clearance (CrCl) < 60 mL/min (estimated with the Cockroft-Gault equation). 12. Hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.0 x the upper limit of normal (ULN). 13. Recent history or symptoms (within 4 weeks of randomization) of unstable respiratory disease (e.g., pneumonia, product-use associated lung injury or e-cigarette or vaping use-associated lung injury [EVALI], etc.) 14. Women who are pregnant or breast-feeding. 15. Male or female subjects of childbearing potential who do not agree to use acceptable methods of birth control starting at the time of consent, during the study treatment period, and continuing for one month after ending study treatment. 16. Participation in a clinical study with an investigational drug in the 4 weeks prior to study randomization. 17. Use of other smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy [NRT]) in the 4 weeks prior to study randomization, any previous cytisine use, or planned use of these or other nicotine replacement medications during the study. 18. Any planned use during the study of combustible cigarettes or other nicotine-containing, non-vaping products (e.g., pipe tobacco, cigars, snuff, smokeless tobacco, hookah, ZYN pouches, etc). 19. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
cytisinicline
film-coated oral tablets containing 3 mg cytisinicline
Placebo
film-coated oral tablets containing matched placebo
Behavioral:
Behavioral support
Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.

Locations

Country Name City State
United States Massachusetts General Hospital - Clinical Genetic Research Facility Boston Massachusetts
United States Alliance for Multispecialty Research, LLC Knoxville Tennessee
United States Alliance for Multispecialty Research, LLC Lexington Kentucky
United States Costal Carolina Research Center North Charleston South Carolina
United States Rochester Clinical Research, Inc Rochester New York

Sponsors (1)

Lead Sponsor Collaborator
Achieve Life Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Participants With Vaping Abstinence During Weeks 9 to 12 Vaping abstinence using quantitative saliva cotinine levels at < 10 ng/mL for biochemical verification and participants' self-report of no vaping in the past 7 days. Week 9-12
Secondary Proportion of Participants With Vaping Abstinence During Weeks 3 to 6 Vaping abstinence using quantitative saliva cotinine levels at < 10 ng/mL for biochemical verification and participants' self-report of no vaping in the past 7 days. Weeks 3-6
Secondary Proportion of Participants With Vaping Abstinence During Weeks 6 to 9 Vaping abstinence using quantitative saliva cotinine levels at < 10 ng/mL for biochemical verification and participants' self-report of no vaping in the past 7 days. Weeks 6-9
Secondary Number of Participants Who Achieve Vaping Abstinence at Any Time Between Week 2 and Week 12 (Seven-Day Point Prevalence Rates) Vaping abstinence using quantitative saliva cotinine levels at < 10 ng/mL for biochemical verification and participants' self-report of no vaping in the past 7 days. Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Secondary Changes From Baseline in Quantitative Cotinine Levels from Week 2 to Week 12 Changes in nicotine vaping using weekly quantitative cotinine levels from Week 2 to Week 12. Baseline, Weeks 2-12
Secondary Proportion of Participants With Vaping Abstinence During Weeks 9 to 16 Vaping abstinence using quantitative saliva cotinine levels at < 10 ng/mL for biochemical verification and participants' self-report of no vaping in the past 7 days. Weeks 9 to 16
See also
  Status Clinical Trial Phase
Completed NCT05037656 - Testing a School-Based E-cigarette, Tobacco, and Betel (Areca) Nut Use Prevention Curriculum for Guam Youths N/A
Recruiting NCT05454267 - Early Detection of Vaping-related Vascular Diseases
Enrolling by invitation NCT04678245 - Network Intervention to Prevent Vaping N/A
Recruiting NCT06297005 - The Impact of E-cigarettes During Pregnancy on Childhood Health Outcomes Study
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Completed NCT04522362 - Modeling Stress-precipitated Vaping Behavior N/A
Completed NCT04054765 - A Virtual Reality Videogame for E-cigarette Prevention in Teens N/A
Recruiting NCT06291597 - Vaping Adverse Lung and Heart Events Cohort
Active, not recruiting NCT04919590 - Text Message Quit Vaping Intervention for Adolescents N/A
Completed NCT04568395 - Acute Effects of TCIG vs ECIG in PLWH N/A
Completed NCT04707911 - Social Media Intervention to Stop Nicotine and Cannabis Vaping Among Adolescents N/A
Withdrawn NCT04340700 - Characterization of the Pharmacodynamic Response to Vaped THC Phase 3
Not yet recruiting NCT06335329 - Point-of-Care Ultrasound (POCUS) Findings and Impact on Vaping N/A
Completed NCT06433466 - Influencer Marketing: a Survey-based Experiment N/A
Active, not recruiting NCT05488743 - Smoking Prevention Program in Poland
Terminated NCT05240027 - To Vape or Not to Vape N/A
Recruiting NCT04661683 - Secondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol N/A
Completed NCT04450537 - PACE Vape Messaging Study N/A
Active, not recruiting NCT05367492 - Varenicline for Nicotine Vaping Cessation in Adolescents Phase 4
Completed NCT04879225 - Menthol and Mint Experimental Tobacco Marketplace (ETM) Study N/A